Bausch Health Companies INC 8-K filings

Michael Goettler has resigned from the Bausch Health Companies Inc. Board of Directors, effective June 30, 2026, to become President and CEO of Knoa Pharma LLC.

Bausch Health Companies Inc. held its Annual Meeting of Shareholders on May 19, 2026, where shareholders elected directors, approved executive compensation on an advisory basis, and appointed PricewaterhouseCoopers LLP as auditors.

Bausch Health Companies Inc. announced it will settle 2023 performance share unit awards for executives Thomas Appio and Seana Carson in cash rather than stock upon their vesting on March 3, 2026.

Bausch Health announced its global Phase 3 RED-C clinical program for amorphous-rifaximin SSD in hepatic encephalopathy did not meet its primary endpoint.

Bausch Health Companies Inc. announced it will reaffirm its full year 2025 guidance at the higher end of the range during the upcoming J.P. Morgan Healthcare Conference.

Bausch + Lomb Corporation completed a credit agreement refinancing, securing $2.8 billion in new term B loans with reduced interest margins and an extended maturity for a portion of its debt.

Bausch Health Companies Inc. and its subsidiary completed an exchange offer, issuing $1.6 billion in new 10.00% Senior Secured Notes due 2032 and increasing the pledged Bausch + Lomb shares to 60%.

Bausch Health Companies Inc. successfully concluded its exchange offers for senior secured notes, issuing approximately $1.6 billion in new notes due 2032.

Bausch + Lomb announced a $2.8 billion debt refinancing, securing lower interest rates and extending maturity for a portion of its term loans.

Bausch Health Companies Inc. announced early results for its debt exchange offer, with tendered notes exceeding the maximum new notes amount.

Bausch Health Companies Inc. announced an offer to exchange up to $1.6 billion of its 2028 senior secured notes for new 10.00% senior secured notes due 2032 to manage intermediate term debt maturities.

Bausch Health Companies Inc. reported a 7% increase in third-quarter 2025 consolidated revenues to $2.68 billion and raised its full-year financial guidance.

Bausch Health Companies Inc. shareholders approved the adoption of the Amended and Restated Shareholder Rights Plan Agreement at a Special Meeting held on October 7, 2025.

Bausch Health Companies Inc. announced the successful completion of its tender offer and subsequent merger with DURECT Corporation.

Bausch Health Companies Inc. announced the termination of its agreement with Icahn Group, leading to the resignation of two directors, while Paulson Capital Inc. significantly increased its shareholding.

Bausch Health Companies Inc. announced robust second quarter 2025 financial results, including a 5% increase in consolidated revenues and a significant rise in net income, while reaffirming and increasing its full-year guidance.

Bausch Health Companies Inc. announced a definitive agreement to acquire DURECT Corporation, gaining larsucosterol, a novel therapeutic with FDA Breakthrough Therapy Designation for alcoholic hepatitis.

Bausch Health Companies Inc. announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, increasing the board size from ten to twelve members.

Bausch Health Companies Inc. announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025.

Bausch + Lomb Corporation's subsidiaries have successfully completed an upsized €675 million senior secured notes offering and a significant credit agreement refinancing, extending maturities and enhancing financial flexibility.

Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced the pricing of an upsized $675 million senior secured notes offering and increased new term B loan facility to $2.325 billion, aimed at refinancing existing debt.

Bausch + Lomb Corporation announced a $600 million senior secured floating rate notes offering and a partial refinancing of its credit agreement, including new term B and revolving credit facilities, to repay existing debt and for general corporate purposes.

Bausch Health Companies Inc. has entered into letter agreements with Carl Icahn, John Paulson, and Sarah Kavanagh to prevent proxy contests and ensure their support for management nominees on the Bausch + Lomb Corporation board.

John S. Barresi, Senior Vice President, Controller, and Chief Accounting Officer of Bausch Health Companies Inc., has resigned, effective June 2, 2025, to pursue another opportunity.

Bausch Health held its Annual Meeting of Shareholders on May 13, 2025, where shareholders elected directors, approved executive compensation, and ratified the employee stock purchase plan and auditor appointment.

Bausch Health announced a 5% increase in first quarter 2025 consolidated revenues, alongside ongoing efforts to enhance shareholder value and optimize its capital structure.

Bausch Health Companies Inc. has adopted a shareholder rights plan to ensure fair treatment of all shareholders in the event of an unsolicited takeover bid.

Bausch Health Companies Inc. finalizes a $4.4 billion notes offering and establishes new credit facilities to refinance existing debt and for general corporate purposes.

Bausch Health Companies Inc. announced the pricing of an upsized $4.4 billion private offering of senior secured notes due 2032 to refinance existing debt and for general corporate purposes.

Bausch Health Companies Inc. announces the launch of a $4.0 billion senior secured notes offering and new senior secured credit facilities to refinance existing debt and for general corporate purposes.